# FDA Approves Datopotamab Deruxtecan for First-Line Immunotherapy-Ineligible Triple-Negative Breast Cancer

> fda · REPORTED · 2026-07-01

The FDA granted first-line approval for datopotamab deruxtecan for immunotherapy-ineligible triple-negative breast cancer patients, expanding treatment options for a historically difficult-to-treat patient population without PD-L1 expression. The approval reflects continued FDA momentum on antibody-drug conjugates for breast cancer in 2026.

About AstraZeneca / FDA: AstraZeneca and Daiichi Sankyo co-develop datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate designed to deliver cytotoxic therapy selectively to triple-negative breast cancer cells, addressing patients who are ineligible for checkpoint immunotherapy.

- Company: AstraZeneca / FDA
- Sector: oncology
- Primary source: https://www.ajmc.com/compendium/womens-health

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.